172 related articles for article (PubMed ID: 37583830)
21. Novel Exatecan-Derived Topoisomerase-1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 May; 15(5):579-580. PubMed ID: 38746899
[TBL] [Abstract][Full Text] [Related]
22. Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma.
Sabnis RW
ACS Med Chem Lett; 2023 Oct; 14(10):1336-1337. PubMed ID: 37849559
[TBL] [Abstract][Full Text] [Related]
23. Novel IRAK4 Inhibitors for Treating Asthma, COPD, Cancer, Autoinflammatory Diseases, and Autoimmune Diseases.
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1617-1618. PubMed ID: 38116447
[TBL] [Abstract][Full Text] [Related]
24. Novel Pyrido[3,2-
Sabnis RW
ACS Med Chem Lett; 2023 Dec; 14(12):1627-1628. PubMed ID: 38116408
[TBL] [Abstract][Full Text] [Related]
25. Novel Furopyridine and Furopyrimidine Compounds as PI4K Inhibitors for Treating Malaria and Viral Infection.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):779-780. PubMed ID: 38894915
[TBL] [Abstract][Full Text] [Related]
26. Novel Tetrahydropyrido[3,4-
Sabnis RW
ACS Med Chem Lett; 2024 Mar; 15(3):318-319. PubMed ID: 38505843
[TBL] [Abstract][Full Text] [Related]
27. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Feb; 15(2):177-178. PubMed ID: 38352847
[TBL] [Abstract][Full Text] [Related]
28. Novel Myeloperoxidase Inhibitors for Treating Multiple Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 May; 15(5):569-570. PubMed ID: 38746891
[TBL] [Abstract][Full Text] [Related]
29. Nitrogen-Containing 2,3-Dihydroquinazolinone Compounds as Na
Sabnis RW
ACS Med Chem Lett; 2023 Jul; 14(7):893-894. PubMed ID: 37465303
[TBL] [Abstract][Full Text] [Related]
30. Fused Bicyclic Heteroaryl Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
Sabnis RW
ACS Med Chem Lett; 2023 Jul; 14(7):895-896. PubMed ID: 37465294
[TBL] [Abstract][Full Text] [Related]
31. Novel ACC Inhibitors for Treating Acne.
Sabnis RW
ACS Med Chem Lett; 2024 Apr; 15(4):445-446. PubMed ID: 38628789
[TBL] [Abstract][Full Text] [Related]
32. Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Apr; 15(4):443-444. PubMed ID: 38628783
[TBL] [Abstract][Full Text] [Related]
33. Combination of Allosteric and Orthosteric EGFR Inhibitors for Treating Non-Small-Cell Lung Cancer.
Sabnis RW
ACS Med Chem Lett; 2024 Mar; 15(3):342-343. PubMed ID: 38505844
[TBL] [Abstract][Full Text] [Related]
34. Novel HSD17B13 Inhibitors for Treating Liver Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Jun; 15(6):771-772. PubMed ID: 38894932
[TBL] [Abstract][Full Text] [Related]
35. Novel Heterocyclic PAD4 Inhibitors for Treating Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Mar; 15(3):340-341. PubMed ID: 38505857
[TBL] [Abstract][Full Text] [Related]
36. Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases.
Sabnis RW
ACS Med Chem Lett; 2024 Feb; 15(2):179-180. PubMed ID: 38352837
[TBL] [Abstract][Full Text] [Related]
37. Novel Haloacethydrazides as AEP Inhibitors for Treating Alzheimer's Disease.
Sabnis RW; Sabnis AR
ACS Med Chem Lett; 2023 Sep; 14(9):1165-1166. PubMed ID: 37736172
[TBL] [Abstract][Full Text] [Related]
38. Protease Inhibitors for Treating or Preventing Coronavirus Infection.
Sabnis RW
ACS Med Chem Lett; 2023 Nov; 14(11):1489-1490. PubMed ID: 37974953
[TBL] [Abstract][Full Text] [Related]
39. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
Sabnis RW
ACS Med Chem Lett; 2023 Aug; 14(8):1043-1044. PubMed ID: 37583831
[TBL] [Abstract][Full Text] [Related]
40. Novel Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.
Sabnis RW
ACS Med Chem Lett; 2023 Jul; 14(7):891-892. PubMed ID: 37465297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]